There were 252 press releases posted in the last 24 hours and 431,636 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase I/II Clinical Trial of ATSN-101 in LCA1 Published in The Lancet

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image